1. Home
  2. PRAX vs NVTS Comparison

PRAX vs NVTS Comparison

Compare PRAX & NVTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$263.71

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Navitas Semiconductor Corporation

NVTS

Navitas Semiconductor Corporation

HOLD

Current Price

$23.68

Market Cap

7.3B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
NVTS
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
7.3B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
PRAX
NVTS
Price
$263.71
$23.68
Analyst Decision
Strong Buy
Buy
Analyst Count
15
5
Target Price
$572.13
$6.68
AVG Volume (30 Days)
427.5K
33.8M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$45,916,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7,758.26
$71.28
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$37.25
$5.44
52 Week High
$366.52
$34.17

Technical Indicators

Market Signals
Indicator
PRAX
NVTS
Relative Strength Index (RSI) 39.24 51.45
Support Level $157.29 $23.59
Resistance Level $342.62 $34.00
Average True Range (ATR) 21.68 3.07
MACD -6.71 -1.00
Stochastic Oscillator 20.77 25.68

Price Performance

Historical Comparison
PRAX
NVTS

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About NVTS Navitas Semiconductor Corporation

Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components. Geographically, the company operates in Hong Kong, China, Europe, the United States, Rest of Asia, and Others. The majority of revenue is generated from Hong Kong.

Share on Social Networks: